Contact WAO | e-News Sign Up | Site Map | Home  
World Allergy Organization
WAO's mission: To be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies.

Medical Journal Reviews

September 2014

Articles are selected for their importance to clinicians who care for patients with asthma and allergic/immunologic diseases by Juan Carlos Ivancevich, MD, WAO Web Editor-in-Chief, and John J. Oppenheimer, MD - FACAAI - FAAAAI, WAO Reviews Editor. 

1. Toll-like receptors (TLR) agonists and antagonists exhibit anti-asthma/allergic rhinitis effects.

Aryan Z, Holgate ST, Radzioch D and Rezaei N. A new era of targeting the ancient gatekeepers of the immune system: toll-Like agonists in the treatment of allergic rhinitis and asthma. International Archives of Allergy and Immunology 2014; 164(1): 46-63. (doi:10.1159/000362553)

Full Text, Free

Editor’s comment: The authors review the current literature and explore the potential development of agonists and antagonists of TLRs.  It is hopeful that these future agents will provide major therapeutic tools to modulate the natural course of allergic disease.

2. Anaphylaxis: Mast cell activation and mast cell mediators on the cardiovascular system.

Triggiani M, Montagni M, Parente R, and Ridolo E. Anaphylaxis and cardiovascular diseases: a dangerous liaison. Current Opinion in Allergy & Clinical Immunology 2014; 14(4): 309-315. (doi:10.1097/ACI.0000000000000071)


Editor’s comment: This comprehensive review summarizes the most recent clinical and experimental data regarding cardiovascular involvement during anaphylaxis.

3. Antihistamines and level of cardiovascular safety.

Olasinska-Wisniewska A, Olasinski J, and Grajek S. Cardiovascular safety of antihistamines. Advances in Dermatology and Allergology / Post?py Dermatologii i Alergologii 2014; 31(3): 182-186. (doi:10.5114/pdia.2014.43191)

Full Text, Free

Editor’s comment: This review evaluates the new generation of antihistamine drugs in the context of QT interval prolongation risk.

4. Promising treatments for anterior ocular inflammatory disease.

Syed BA, Kumar S, and Bielory L. Current options and emerging therapies for anterior ocular inflammatory disease. Current Opinion in Allergy & Clinical Immunology 2014; 14(5): 485-489. (doi:10.1097/ACI.0000000000000097)


Editor’s comment: This article reviews the current available agents as well as medicines “in the pipeline” for the treatment of anterior ocular inflammatory disease (allergic conjunctivitis, uveitis and dry eye syndrome).

5. Operational classification and a practical diagnostic algorithm of irritant-induced asthma (IIA).

Vandenplas O, Wiszniewska M, Raulf M, de Blay F, van Wijk RG et al. EAACI position paper: irritant-induced asthma. Allergy 2014; 69(9): 1141-1153. (doi:10.1111/all.12448)

Full Text, Free

Editor’s comment: This document, prepared by a panel of experts, summarizes our current knowledge regarding the epidemiology, pathophysiology, diagnosis and management of irritant-induced asthma.